Cancer Family
Lung Neoplasm
CI-CAN-00000221Explore in graph →
Non-malignant2,726 active trials51 approved drugs619 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000221Explore in graph →
Clinical trials
11,603 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03647098 | Survival Outcomes of Lung Cancer(Soul) | recruiting | — | 20,000 | Hunan Province Tumor HospitalOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT04616209 | Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients | recruiting | Phase 1 / Phase 2 | 24 | Precision Biotech Taiwan Corp.INDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT05104515 | First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine | recruiting | Phase 1 | 36 | Oxford Vacmedix UK Ltd.INDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT06827145 | Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC | active not recruiting | Phase 2 | 30 | National Cancer Center, ChinaOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT06827639 | In-depth Characterization of Circulating and Infiltrating Immune Subsets and Tumor Cells in Cancer Patients(FUTURE) | not yet recruiting | — | 640 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT05669430 | A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies | recruiting | Phase 1 / Phase 2 | 365 | GV20 TherapeuticsINDUSTRY | 1 | Feb 13, 2025 | clinicaltrials |
| NCT06818955 | Orlistat Overcoming Third-generation EGFR-TKI Resistance(OOTER) | not yet recruiting | Phase 2 | 36 | Ping PengOTHER | 0 | Feb 12, 2025 | clinicaltrials |
| NCT06823245 | Pharmacokinetic Study of HS-10241 Tablets in Subjects with Hepatic Impairment and Normal Hepatic Function | not yet recruiting | Phase 1 | 32 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 0 | Feb 12, 2025 | clinicaltrials |
| NCT06823258 | Pharmacokinetic Study of HS-10365 Capsule in Subjects with Hepatic Impairment and Normal Hepatic Function | not yet recruiting | Phase 1 | 32 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 0 | Feb 12, 2025 | clinicaltrials |
| NCT05257967 | CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease | recruiting | N/A | 10 | British Columbia Cancer AgencyOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT06613009 | Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer | recruiting | Phase 1 | 190 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 2 | Feb 11, 2025 | clinicaltrials |
| NCT06789796 | a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy. | not yet recruiting | Phase 3 | 636 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Feb 11, 2025 | clinicaltrials |
| NCT06820762 | Irinotecan Liposome(II) Combined With Ivonescimab as Second-line Treatment for Small Cell Lung Cancer : A Prospective, Single-arm, Multicenter Clinical Study | not yet recruiting | Phase 2 | 40 | The Second Affiliated Hospital of Dalian Medical UniversityOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT06714708 | Low Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC | recruiting | Phase 2 | 86 | Anhui Provincial Cancer HospitalOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06816966 | Chemotherapy-immunotherapy-based Split-course Adaptive Hypofractionated Radiotherapy for Extensive-stage SCLC(CISART) | enrolling by invitation | Phase 2 | 35 | Fujian Medical University Union HospitalOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06818149 | Biomarkers for Clinical Classification and Outcomes of Immune Checkpoint Inhibitor-Related-Related Myocarditis in Lung Cancer | recruiting | — | 50 | Shanghai Chest HospitalOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT04886401 | Retrospective Observational Study on Prediction of Response to PD-1 Immunotherapy in Patients with NSCLC(PREDICTION) | recruiting | — | 50 | University Hospital, BrestOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT06803381 | Somesthesia in Cancer Patients: Variability and Influence on Eating Experience(SOMEST'ALIM2) | not yet recruiting | — | 96 | Hospices Civils de LyonOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT06813144 | Effectiveness of Respiratory Muscle Training with a Mobile Application After Lobectomy | not yet recruiting | N/A | 45 | Hacettepe UniversityOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT06082492 | The Beneficial Value of PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients(NVALT31-PET) | recruiting | N/A | 690 | Radboud University Medical CenterOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT06808113 | Circulating and Molecular Markers Involved in the Processes of Cachexia, Anorexia and Sarcopenia in Patients With NSCLC(SARCLUNG) | active not recruiting | — | 40 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT04878445 | Tissue Engineering Approaches to Treat COPD | active not recruiting | — | 30 | University Hospitals of North Midlands NHS TrustOTHER | 1 | Feb 4, 2025 | clinicaltrials |
| NCT06807307 | Transcriptional Framework for the Molecular Diagnosis of Response to Immunotherapy in Lung Cancer With Agnostic Potential(KEAPnes) | recruiting | — | 256 | Regina Elena Cancer InstituteOTHER | 1 | Feb 4, 2025 | clinicaltrials |
| NCT03212404 | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | active not recruiting | Phase 1 | 272 | Checkpoint Therapeutics, Inc.INDUSTRY | 9 | Feb 3, 2025 | clinicaltrials |
| NCT03740503 | Genomic Investigation of Unusual Responders(GENIUS) | recruiting | — | 100 | University Health Network, TorontoOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT06802627 | Prehabilitation for Lung Cancer Patients Undergoing Lung Resection(Fit4LungNeo) | not yet recruiting | N/A | 200 | Universidade do PortoOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT03944772 | Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)(ORCHARD) | active not recruiting | Phase 2 | 247 | AstraZenecaINDUSTRY | 9 | Jan 30, 2025 | clinicaltrials |
| NCT05819346 | Digital Lifestyle Intervention for Lung Cancer Survivors(QUALUCA) | recruiting | N/A | 88 | Kai-Uwe Schmitt, PhD, MEng, ICIDOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06341933 | Risk Factors for AKI in Patients Undergoing VATS for Pulmonary Resection | recruiting | — | 100 | Atatürk Chest Diseases and Chest Surgery Training and Research HospitalOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT04597671 | Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28)(NVALT28) | active not recruiting | Phase 3 | 170 | Association NVALT StudiesOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT05654675 | Evaluation of the Use of the FUR to Quantify Tumor Glucose Consumption in Oncologic PET | recruiting | — | 30 | Academisch Ziekenhuis MaastrichtOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06484972 | A Study to Evaluate Guideline Adoption Through Quality Improvement Project (QIP) in Pulmonary and Critical Care Medicine (PCCM) Department(LC PCCM QIP) | not yet recruiting | — | 1,728 | China-Japan Friendship HospitalOTHER | 0 | Jan 28, 2025 | clinicaltrials |
| NCT06630611 | Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL)(PragmaTIL) | recruiting | Phase 2 | 40 | Vall d'Hebron Institute of OncologyOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT04324164 | Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC | recruiting | — | 800 | Hunan Province Tumor HospitalOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT05341557 | A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma | recruiting | Phase 1 | 110 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 27, 2025 | clinicaltrials |
| NCT05504278 | Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation | recruiting | Phase 1 | 144 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jan 27, 2025 | clinicaltrials |
| NCT06793228 | Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia | not yet recruiting | Phase 2 | 250 | Henan Cancer HospitalOTHER_GOV | 1 | Jan 27, 2025 | clinicaltrials |
| NCT06793813 | Cadonilimab in Patients (Pts) with Advanced Non-small Cell Lung Cancer (NSCLC) | recruiting | Phase 2 | 44 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT06794957 | A Study of AL8326 in Non-Small Cell Lung Cancer | active not recruiting | Phase 1 | 158 | Advenchen Laboratories, LLCINDUSTRY | 1 | Jan 27, 2025 | clinicaltrials |
| NCT06790797 | Investigating the Biomarkers in Tumor and Peripheral Blood to Evaluate the Efficacy of Cancer Immunotherapy in Chest Cancer Patients | recruiting | — | 50 | Zhao JunOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT06071013 | Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients | recruiting | Phase 1 / Phase 2 | 20 | China Medical University HospitalOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06758557 | A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 282 | Huabo Biopharm Co., Ltd.INDUSTRY | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06788366 | AI-HOPE Lung Cancer: Building a Predictive Tool for Metastatic Lung Cancer | recruiting | — | 2,000 | IRCCS San RaffaeleOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06789276 | The Impact of Thoracic Paravertebral Nerve Block At Different Positions on Pain Relief in Patients Undergoing Single-Port Thoracoscopic Partial Lung Resection | not yet recruiting | N/A | 200 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06789562 | F-18 FDG PET/CT and CT in Initial Staging of Non-small Lung Cancer | not yet recruiting | — | 54 | Assiut UniversityOTHER | 0 | Jan 23, 2025 | clinicaltrials |
| NCT06786208 | Real-world Study of Sunvozertinib Treatment in Advanced EGFR-Mutant NSCLC After EGFR-TKI Treatment Failure | not yet recruiting | — | 55 | Henan Cancer HospitalOTHER_GOV | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06786312 | A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer | not yet recruiting | Phase 2 | 34 | Fujian Cancer HospitalOTHER_GOV | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06786468 | Standard Care With or Without Early Palliative Care Provided by Palliative Care Specialist in Advanced Non-small Cell Lung Cancer Patients | recruiting | N/A | 104 | Mahidol UniversityOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06785584 | Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma ：A Multicenter, Real-World Clinical Study | not yet recruiting | Phase 4 | 30 | Fujian Medical University Union HospitalOTHER | 1 | Jan 21, 2025 | clinicaltrials |
| NCT06684418 | Artificial Intelligence-based Model for the Prediction of Occult Lymph Node Metastasis and Improvement of Clinical Decision-making in Non-small Cell Lung Cancer | recruiting | — | 6,000 | Fudan UniversityOTHER | 1 | Jan 20, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 14, 2025source: clinicaltrials